The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications
Open accessAbstract
MicroRNAs (miRNAs) have emerged as key genetic regulators of a wide variety of biological processes, including growth, proliferation, and survival. Recent advances have led to the recognition that miRNAs can act as potent oncogenes and tumor suppressors, playing crucial roles in the initiation, maintenance, and progression of the oncogenic state in a variety of cancers. Determining how miRNA expression and function is altered in cancer is an important goal, and a necessary prerequisite to the development and adoption of miRNA-based therapeutics in the clinic. Highly promising clinical applications of miRNAs are the use of miRNA signatures as biomarkers for cancer (for example, for early detection or diagnosis), and therapeutic supplementation or inhibition of specific miRNAs to alter the cancer phenotype. In this review, we discuss the main methods used for miRNA profiling, and examine key miRNAs that are commonly altered in a variety of tumors. Current studies underscore the functional versatility and potency of miRNAs in various aspects of the cancer phenotype, pointing to their potential clinical applications. Consequently, we discuss the application of miRNAs as biomarkers, clinical agents, and therapeutic targets, highlighting both the enormous potential and major challenges in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242606799 · Cited by 5,111
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
MicroRNA Gene Expression Deregulation in Human Breast Cancer
Iorio, M. V., Ferracin, M., Liu, C.-G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, M., Fabbri, M., Campiglio, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1783 · Cited by 4,053
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882
Sibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma
Medina, P. P., Nolde, M., & Slack, F. J. (2010) · Nature · doi:10.1038/nature09284 · Cited by 971
Self-citationMicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., & Krichevsky, A. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00479-08 · Cited by 888 · cited 3×
“miR-21 has been identified as being upregulated in glioblastomas, and miR-21 knockdown in glioblastoma cell lines results in caspase activation and elevated apoptotic rates, indicating a pro-survival function for miR-21 [44-48].”
BackgroundPeltier, H. J., & Latham, G. J. (2008) · RNA · doi:10.1261/rna.939908 · Cited by 820
Boeri, M., Verri, C., Conte, D., Roz, L., Modena, P., Facchinetti, F., Calabrò, E., Croce, C. M., Pastorino, U., & Sozzi, G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100048108 · Cited by 722
MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells
Papagiannakopoulos, T., Shapiro, A., & Kosik, K. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1305 · Cited by 705 · cited 2×
“miR-21 has been identified as being upregulated in glioblastomas, and miR-21 knockdown in glioblastoma cell lines results in caspase activation and elevated apoptotic rates, indicating a pro-survival function for miR-21 [44-48].”
BackgroundModulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.013 · Cited by 626 · cited 5×
“miR-21 can target the potent tumor suppressor gene PTEN, as well as negative regulators of the RAS signaling axis including Spry1, Spry2, and Btg2, enhancing cell proliferation [38,39].”
BackgroundInfluentialMiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500
Comparison of Reverse Transcriptases in Gene Expression Analysis
Ståhlberg, A., Kubista, M., & Pfaffl, M. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.035469 · Cited by 240
The role of matrix metalloproteinases in glioma invasion
Nakada, M. (2003) · Frontiers in Bioscience · doi:10.2741/1016 · Cited by 201
Intact p53-Dependent Responses in miR-34–Deficient Mice
Concepcion, C. P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J. A., Maughan, W. P., Ogrodowski, P., & Ventura, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002797 · Cited by 197
Cited by
MicroRNAs in cancer: biomarkers, functions and therapy
Hayes, J., Peruzzi, P. P., & Lawler, S. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.005 · Cited by 2,049
The circ RNA–micro RNA code: emerging implications for cancer diagnosis and treatment
Verduci, L., Strano, S., Yarden, Y., & Blandino, G. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12468 · Cited by 438
Role of microRNAs in translation regulation and cancer
Oliveto, S., Mancino, M., Manfrini, N., & Biffo, S. (2017) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v8.i1.45 · Cited by 431
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Rynkeviciene, R., Simiene, J., Strainiene, E., Stankevicius, V., Usinskiene, J., Miseikyte Kaubriene, E., Meskinyte, I., Cicenas, J., & Suziedelis, K. (2018) · Cancers · doi:10.3390/cancers11010017 · Cited by 136
Metadata
- Authors
- Stahlhut, C., & Slack, F. J.
- Venue
- Genome Medicine
- Published
- 2013
- Volume
- 5
- Issue
- 12
- Pages
- 111
- ISSN
- 1756-994X (ISSN-L)
- OpenAlex
- W2165759865
- Cited by
- 174
- References
- 18
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.